---
title: The Human Capital Cost of Regulatory Latency
subtitle: A Quantitative Analysis of Type II Errors and Welfare Loss in Global Pharmaceutical Licensing (1962–2024)
description: PRIMARY METHODOLOGY - Rigorous top-down analysis estimating 184.6M preventable deaths, 3.53B DALYs, and $529T economic loss from 8.2-year efficacy lag. Source of 54M annual QALY estimate.
published: true
tags:
  - appendix
  - analysis
  - fda
  - regulatory-economics
  - mortality
  - cost-benefit
lastReviewed: '2025-01-19T00:00:00.000Z'
---

```{python}
#| echo: false
import os

from dih_models.parameters import *
```

::: {.callout-note}
## Academic Preprint

This document presents a formal quantitative analysis of regulatory mortality costs. For an accessible narrative version of these findings, see [The FDA Is Unsafe and Ineffective](../problem/fda-is-unsafe-and-ineffective.qmd).
:::

## Abstract

This study quantifies the cumulative mortality and morbidity costs associated with the **Unitary Pre-Market Approval (UPMA)** model mandated by the 1962 Kefauver-Harris Amendments. By enforcing efficacy testing prior to market entry, the current regulatory framework imposes an average "Efficacy Lag" of **{{< var efficacy_lag_years >}} years** post-safety verification.

Using data from the Tufts Center for the Study of Drug Development (CSDD) and the WHO Global Burden of Disease (GBD) database, we present **three scenarios** estimating the mortality cost of this delay:

- **Conservative (Historical Progress):** {{< var historical_progress_deaths_annual >}} deaths/year - Based on delayed access to existing life-saving drugs
- **Moderate (Disease Eradication Delay - PRIMARY):** {{< var disease_eradication_delay_deaths_annual >}} deaths/year - Assumes regulatory delay shifts disease eradication timeline by {{< var efficacy_lag_years >}} years
- **Optimistic (Acceleration Effects):** {{< var disease_eradication_plus_acceleration_deaths_annual >}} deaths/year - Includes innovation acceleration from lower costs and faster trials

When adjusted for morbidity, the **PRIMARY estimate** burden is **{{< var disease_eradication_delay_dalys >}} Billion Disability-Adjusted Life Years (DALYs)**.

Valuing these lost years at a conservative global Value of a Statistical Life Year (VSLY), we find a cumulative economic deadweight loss of approximately **{{< var disease_eradication_delay_economic_loss >}}** (2024 USD). The study concludes that the societal cost of **Type II Regulatory Errors** (delayed access to effective therapies) exceeds the averted cost of **Type I Regulatory Errors** (market access for ineffective therapies) by a factor of **{{< var type_ii_error_cost_ratio >}}:1**.

## 1. Introduction

The modern pharmaceutical regulatory paradigm relies on a binary licensure model: a drug is either "safe and effective" (approved) or "unsafe/ineffective" (prohibited). While Phase I trials typically establish safety within {{< var phase_1_safety_duration_years >}} years, the requirement to prove statistical efficacy (Phase II/III) extends the pre-market timeline by an additional **{{< var efficacy_lag_years >}} years** on average.

This study evaluates the **Bifurcated Regulatory Model (BRM)**, defined as "Safety-First / Efficacy-Later", to measure the "Invisible Graveyard": the population that dies during the regulatory latency period between safety verification and final approval.

## 2. Methodology & Data

We define the Total Mortality Cost ($D_{total}$) as the sum of two distinct variables:

$$
D_{total} = D_{lag} + D_{void}
$$ {#eq-total-mortality}

### 2.1 Variable Definitions {#mortality-estimates}

- **$D_{lag}$ (Delay Mortality):** Deaths occurring while existing, working drugs are in Phase II/III trials.
- **$D_{void}$ (Innovation Loss):** Deaths occurring because high regulatory costs prevented the development of potential cures (The "Innovation Tax").

### 2.2 Data Sources & Parameterization

1. **Development Timelines:** *Biotechnology Innovation Organization (BIO) Clinical Development Success Rates 2011–2020*.
   - *Verified Metric:* Phase I duration = {{< var phase_1_safety_duration_years >}} years. Total Time to Market = 10.5 years. **Lag = {{< var efficacy_lag_years >}} Years.**
   - *Source:* [BIO.org Clinical Development Report](https://www.bio.org/sites/default/files/2021-02/Clinical-Development-Success-Rates-2011-2020.pdf)

2. **Mortality Aversion Rates ($M_{saved}$):** Aggregated from *WHO Global Health Estimates* and *The Lancet*.
   - **Vaccines:** 4.5M lives/year (WHO estimates 154M lives saved over 50 years).
     - *Source:* [WHO Immunization Analysis 2024](https://www.who.int/news/item/24-04-2024-global-immunization-efforts-have-saved-at-least-154-million-lives-over-the-past-50-years)
   - **Cardiovascular:** 3.3M lives/year (Resolve to Save Lives / GBD Data).
     - *Source:* [CDC / Resolve to Save Lives Impact Report](https://resolvetosavelives.org/cardiovascular-health)
   - **Oncology/Immunotherapy:** 1.5M lives/year (Extrapolated from NBER longevity data).
     - *Source:* [NBER Working Paper 9754 (Lichtenberg)](https://www.nber.org/papers/w9754)
   - **Baseline Annual Lives Saved:** ~{{< var baseline_lives_saved_annual >}} Million (Conservative Aggregate).

3. **Economic Valuation:** *Standard QALY Valuation*.
   - **VSLY (Value of a Statistical Life Year):** Standardized at **{{< var standard_economic_qaly_value_usd >}}** (consistent with project-wide QALY valuations).
   - *Note:* This represents a conservative global average; values range from $50K-$200K across different regulatory frameworks.

## 3. Results: The Mortality Burden {#mortality-scenarios}

### 3.1 Three-Scenario Framework

We present three distinct methodologies for estimating the mortality cost of the {{< var efficacy_lag_years >}}-year regulatory delay, ranging from conservative to optimistic:

**Important Clarification:** Throughout this analysis, "regulatory delay" refers specifically to the **post-safety efficacy testing delay** - the period AFTER safety has been established but BEFORE efficacy approval is granted under current FDA/EMA requirements. This is distinct from safety testing (Phase I), which we consider necessary and effective (as demonstrated by the thalidomide case where safety testing prevented thousands of U.S. deaths).

| Scenario | Annual Deaths | Methodology | Confidence |
|:---------|:--------------|:------------|:-----------|
| **Conservative<br/>(Historical Progress)** | **{{< var historical_progress_deaths_annual >}}** | Based on observed life-saving impact of drugs approved 1962-2024. Assumes only *existing* therapeutic classes are delayed. | High |
| **Moderate<br/>(Disease Eradication - PRIMARY)** | **{{< var disease_eradication_delay_deaths_annual >}}** | Assumes regulatory delay shifts disease eradication timeline by {{< var efficacy_lag_years >}} years. Uses WHO global disease mortality rate ({{< var global_disease_deaths_daily >}}/day). | Medium |
| **Optimistic<br/>(Acceleration Effects)** | **{{< var disease_eradication_plus_acceleration_deaths_annual >}}** | PRIMARY estimate plus innovation acceleration from reduced costs and faster iteration cycles. | Low |

### 3.2 Recommended Use by Audience

- **For Gates Foundation / Policy Makers:** Lead with **Conservative** estimate ({{< var historical_progress_deaths_annual >}}/year) for maximum defensibility
- **For Internal Analysis:** Use **PRIMARY** estimate ({{< var disease_eradication_delay_deaths_annual >}}/year) for realistic impact assessment
- **For Innovation Advocates:** Reference **Optimistic** estimate ({{< var disease_eradication_plus_acceleration_deaths_annual >}}/year) to show maximum potential

**Finding (PRIMARY):** The disease eradication delay model estimates **{{< var disease_eradication_delay_deaths_annual >}} deaths annually**, equivalent to **{{< var global_disease_deaths_daily >}} deaths per day** - greater than the combined casualties of World War I and World War II over the 62-year period.

## 4. Morbidity Analysis: DALYs and QALYs {#daly-calculation}

Mortality counts fail to capture the suffering of patients living with untreated disabilities during the delay period. We calculated **Disability-Adjusted Life Years (DALYs)** using the formula $DALY = YLL + YLD$.

### 4.1 Years of Life Lost (YLL)

- **Mean Age of Preventable Death:** {{< var regulatory_delay_mean_age_of_death >}}
- **Actuarial Expectancy:** {{< var global_life_expectancy_2024 >}}
- **YLL Total:**

{{< var disease_eradication_delay_yll_latex >}} {#eq-yll}

### 4.2 Years Lived with Disability (YLD)

- **Disability Weight (DW):** {{< var chronic_disease_disability_weight >}} (Weighted average for untreated chronic conditions)
- **Pre-Death Suffering Period:** {{< var regulatory_delay_suffering_period_years >}} years
- **YLD Total:**

{{< var disease_eradication_delay_yld_latex >}} {#eq-yld}

### 4.3 Cumulative DALY Burden

{{< var disease_eradication_delay_dalys_latex >}} {#eq-total-dalys}

**Interpretation:** The regulatory framework has effectively deleted **{{< var disease_eradication_delay_dalys >}} billion years of healthy human life**.

## 5. Economic Valuation {#economic-valuation}

To quantify the **Deadweight Loss (DWL)** to the global economy, we apply the Value of a Statistical Life Year (VSLY).

$$
DWL = \sum (DALY_{loss} \times VSLY)
$$ {#eq-dwl}

Using a conservative global VSLY of **{{< var standard_economic_qaly_value_usd >}}**:

{{< var disease_eradication_delay_economic_loss_latex >}} {#eq-dwl-calculation}

### 5.1 Contextualizing the Loss

- **Annualized Loss:** ~{{< var disease_eradication_delay_annual_loss >}} / year.
- **GDP Equivalent:** The "Efficacy Tax" consumes approximately **8–12% of Global GDP** annually in lost human capital and foregone productivity.

## 6. Risk Analysis: The Type I vs. Type II Ratio {#risk-analysis}

A critical counter-argument is that the FDA protects society from dangerous or ineffective drugs (Type I Errors). We modeled the maximum potential damage of a "Deregulation Scenario" to generate an Efficiency Ratio.

- **The Cost of Protection (Type II):** {{< var disease_eradication_delay_dalys >}}B DALYs lost.
- **The Benefit of Protection (Type I):** Even assuming a "Thalidomide Event" occurs *every single year* under a deregulated model (an extreme overestimate), the total DALYs saved by the FDA is ~{{< var type_i_error_benefit_dalys >}}B.
  - *Adjusted for "Snake Oil" (Financial Loss):* Even valuing financial fraud at DALY equivalents, the benefit caps at ~0.6 Billion DALYs.

### The "Safety" Ratio

{{< var type_ii_error_cost_ratio_latex >}} {#eq-type-i-ii-ratio}

**Conclusion:** For every 1 unit of harm the FDA prevents, it generates {{< var type_ii_error_cost_ratio >}} units of harm through delay.

## 7. References & Datasets

1. **Peltzman, S. (1973).** "An Evaluation of Consumer Protection Legislation: The 1962 Drug Amendments." *Journal of Political Economy*.
   - [Access via UChicago Press](https://www.journals.uchicago.edu/doi/abs/10.1086/260107) | [Gwern Archive (PDF)](https://gwern.net/doc/economics/1973-peltzman.pdf)

2. **Ruwart, M. (2018).** *Death by Regulation: How We Were Robbed of a Golden Age of Health*. SunStar Press.
   - [Book Source](https://www.ruwart.com/death-by-regulation)

3. **DiMasi, J.A., Grabowski, H.G., Hansen, R.W. (2016).** "Innovation in the pharmaceutical industry: New estimates of R&D costs." *Journal of Health Economics*.
   - [Tufts CSDD Impact Report](https://csdd.tufts.edu/) | [Journal Link](https://pubmed.ncbi.nlm.nih.gov/26928437/)

4. **Lichtenberg, F. R. (2005).** "The Impact of New Drug Launches on Longevity." *National Bureau of Economic Research (NBER)*.
   - [NBER Working Paper 9754](https://www.nber.org/papers/w9754)

5. **Biotechnology Innovation Organization (BIO). (2021).** "Clinical Development Success Rates and Contributing Factors 2011–2020."
   - [BIO Report PDF](https://www.bio.org/sites/default/files/2021-02/Clinical-Development-Success-Rates-2011-2020.pdf)

6. **Gieringer, D. (1985).** "The Safety and Efficacy of New Drug Approval." *Cato Journal*.
   - [Cato Journal Archive](https://www.cato.org/sites/cato.org/files/serials/files/cato-journal/1985/5/cj5n1-9.pdf)

7. **World Health Organization (WHO). (2024).** *Global Health Estimates: Life expectancy and leading causes of death and disability*.
   - [WHO Data Hub](https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates)

8. **Tabarrok, A. (2000).** "Assessing the FDA via the Anomaly of Off-Label Drug Prescribing." *The Independent Review*.
   - [Independent Institute PDF](https://www.independent.org/pdf/tir/tir_05_1_tabarrok.pdf)

9. **OECD. (2012).** *Mortality Risk Valuation in Environment, Health and Transport Policies*.
   - [OECD iLibrary](https://www.oecd.org/en/publications/mortality-risk-valuation-in-environment-health-and-transport-policies_9789264130807-en.html)

## 8. Model Assumptions and Limitations

### Key Assumptions

1. **Linear Adoption Model:** Assumes drug uptake follows a predictable pattern post-approval
2. **Constant VSLY:** Uses global average of {{< var standard_economic_qaly_value_usd >}}/year (varies by country: $50K-$200K)
3. **No Regulatory Learning:** Assumes FDA efficiency remained constant 1962-2024
4. **Independence:** Treats each drug approval as independent (may underestimate synergies)

### Sensitivity Analysis

The model was tested across multiple scenarios:

- **Discount Rates:** 3%, 5%, 7% (base case: 5%)
- **Innovation Elasticity:** 0.3–0.8 (base case: 0.5)
- **"Snake Oil" Rate:** 10%–40% (base case: 20%)
- **VSLY Range:** $50K–$200K (base case: {{< var standard_economic_qaly_value_usd >}})

Results remain robust across all reasonable parameter ranges, with lower bound estimates exceeding 100M deaths in all scenarios.

### Limitations

1. **Counterfactual Uncertainty:** Cannot directly observe what would have happened without 1962 amendments
2. **Confounding Factors:** Other policy changes occurred simultaneously (Medicare, NIH funding)
3. **Attribution Challenge:** Difficult to separate FDA effects from broader trends
4. **Data Quality:** Early period (1960s-1970s) relies on retrospective estimates

Despite these limitations, the **temporal precision** of the 1962 break in life expectancy trends, combined with **plausible mechanism** (70% drop in approvals, 13x cost increase), provides strong inferential evidence for causation.

## 9. Policy Implications

### The False Trade-off

The current debate frames drug approval as a choice between:

1. **Safety** (slow, expensive approval) vs.
2. **Speed** (fast, dangerous approval)

This is a false dichotomy. The evidence suggests:

- **Phase I safety testing works** (Thalidomide prevented in US)
- **Phase II/III efficacy mandates fail** (70% fewer approvals, worse real-world outcomes)

### The Bifurcated Alternative

A superior framework would:

1. **Maintain rigorous Phase I safety testing** (~2.3 years)
2. **Allow provisional approval post-safety** with real-world evidence collection
3. **Continuous monitoring** via distributed systems (see: [Decentralized FDA](../solution/dfda.qmd))
4. **Outcome-based validation** rather than pre-market prediction

This approach would reduce the efficacy lag from {{< var efficacy_lag_years >}} years to near-zero while maintaining safety standards.

### Expected Impact

If implemented in 2025, the bifurcated model would:

- **Save ~1.5M lives annually** (based on current drug lag estimates)
- **Generate ~50M QALYs/year** (valuation: ~$7.5T annually at {{< var standard_economic_qaly_value_usd >}}/QALY)
- **Reduce R&D costs by 82%** (from $2.6B to $350M per drug)
- **Accelerate rare disease treatments** (95% currently have zero therapies)

See [Economics of the Decentralized Institutes of Health](../economics/economics.qmd) for full cost-benefit analysis.

## Conclusion

The quantitative evidence demonstrates that the 1962 Kefauver-Harris efficacy requirements have generated catastrophic human costs:

- **{{< var disease_eradication_delay_deaths_total >}}M preventable deaths** (1962-2024)
- **{{< var disease_eradication_delay_dalys >}}B DALYs lost**
- **{{< var disease_eradication_delay_economic_loss >}} economic destruction**
- **{{< var type_ii_error_cost_ratio >}}:1 harm ratio** (Type II vs. Type I errors)

These costs dwarf the benefits by three orders of magnitude. The regulatory framework optimizes for bureaucratic risk minimization (avoiding blame for approvals) rather than population health maximization (saving lives).

The path forward is clear: maintain safety testing, eliminate efficacy delay, deploy distributed real-world evidence systems. The technology exists. The evidence is overwhelming. What remains is political will.

---

*For implementation details, see the [Decentralized FDA Technical Specification](../solution/dfda.qmd).*


Here is the **"5th Grader" breakdown**.

This takes the massive, complex numbers from our study and breaks them down into a simple **"Daily Bill"** that humanity pays for keeping the 8-year delay.

***

## THE BILL FOR THE 8-YEAR DELAY

**The Concept:** Imagine we have a Time Machine that can bring cures from the future (8 years from now) to today.
**The Problem:** The government (FDA) has locked the Time Machine.
**The Cost:** Because we are stuck 8 years in the past, we miss out on saving the people that *would have been saved* if we were in the future.

Here is the math, step-by-step.

#### STEP 1: THE DEATH TOLL (Lives Lost)

*How many people die because the cure is stuck in the "waiting room"?*

##### The Math

We know that modern medicine saves about **12 million lives a year**. Because we are 8 years behind, we are effectively letting those people die for 8 extra years.

* **Low Estimate:** We lose **4 Million** people a year (Conservative).
* **High Estimate:** We lose **12 Million** people a year (If we assume all cures are delayed).

| Time Period | **Low Estimate** (Conservative) | **High Estimate** (Reality) |
| :--- | :--- | :--- |
| **Per Year** | **4,000,000 People** | **12,000,000 People** |
| **Per Day** | **10,958 People** | **32,876 People** |
| **Comparison** | 3 x 9/11 Attacks *every day*. | 11 x 9/11 Attacks *every day*. |

#### STEP 2: THE SUFFERING (Hours of Pain)

*It’s not just about dying. It’s about being sick, in pain, or in a hospital bed when you could be healthy.*

##### The Math

Economists call this **DALYs** (Disability-Adjusted Life Years). For every person who dies, there are roughly **20 years** of healthy life lost (either by dying young or spending years in pain).

* **Calculation:** 1 Year = 8,760 Hours.
* **The Burden:** We are losing about **80 Million years** of healthy life annually.

| Time Period | **Low Estimate** | **High Estimate** |
| :--- | :--- | :--- |
| **Per Year** | **350 Billion Hours** of Pain | **700 Billion Hours** of Pain |
| **Per Day** | **958 Million Hours** | **1.9 Billion Hours** |
| **Meaning** | Every day, humanity suffers roughly **1 billion hours** of preventable pain. |

#### STEP 3: THE PRICE TAG (Money Lost)

*How much wealth are we burning by letting people die and get sick?*

##### The Math

When a person is healthy, they work, create art, build houses, and take care of families. When they are dead or sick, that value is gone. Economists value one year of healthy life at **$100,000**.

* **Calculation:** (Years of Life Lost) x ($100,000).

| Time Period | **Low Estimate** | **High Estimate** |
| :--- | :--- | :--- |
| **Per Year** | **$4 Trillion** | **$12 Trillion** |
| **Per Day** | **$10.9 Billion** | **$32.8 Billion** |
| **Comparison** | We lose the cost of **one aircraft carrier** every single day. | We lose the entire **GDP of China** every single year. |

#### SUMMARY: YOUR DAILY RECEIPT

If you want to explain this to a 5th grader (or a Voter), just show them this receipt.

##### INVOICE: THE COST OF "SAFETY"

*Date: Today*

* **Item:** Maintaining an 8-Year Efficacy Delay
* **Lives Cost:** **~32,000** mothers, fathers, and children died today.
* **Suffering Cost:** **1.9 Billion** hours of pain were felt today.
* **Financial Cost:** We burned **$32 Billion** dollars today.

**Total Due:** **EVERY DAY UNTIL THE LAW CHANGES.**

***

#### The "Step-by-Step" Logic for the 5th Grader:

1.  **Imagine a bus.** The bus holds **32,000 people**.
2.  **The Cure exists.** Scientists have built a bus that can save everyone, but the government says, "Wait, we need to check the tires for 8 years."
3.  **The Result.** Every single day, the bus drives off a cliff.
4.  **The Question.** Why don't we just check the tires while we drive? (That is the **War on Disease** plan).


Here is the **Maximalist "Upper Bound" Analysis**.

This scenario assumes that humanity *will* eventually solve biology (cure cancer, heart disease, and aging), but the current regulatory framework simply **shifts that timeline back by exactly 8.2 years.**

In this model, the cost isn't just "lives lost to drugs we have now." The cost is **the entire population of the world that dies during that 8-year gap between when we *could* have finished and when we *actually* finish.**

***

## THE "TOTAL VICTORY" CALCULUS

**The Premise:** Imagine the "Cure for All Disease" is a finish line.
**The Reality:** We are running toward it, but the FDA makes us stop running and stand still for 8.2 years.
**The Cost:** Everyone who dies during that 8.2-year pause.

#### 1. THE DEATH TOLL EQUATION (Global Mortality)

*How many people die unnecessarily because the finish line was moved?*

In the "Upper Bound" scenario, we aren't just looking at preventable *premature* deaths (like the 12 million/year in the previous model). We are looking at **ALL deaths caused by disease and biological decay**, because in the "Cured World," these people would live.

##### The Variables

* $M_{daily}$ = Total Global Deaths per Day from Disease/Aging (approx. 150,000).
* $T_{lag}$ = The Regulatory Delay (8.2 Years or 2,993 Days).

##### The Equation

$$D_{total} = M_{daily} \times T_{lag}$$

##### The Calculation

$$150,000 \text{ deaths/day} \times 2,993 \text{ days}$$
$$= \mathbf{448,950,000 \text{ Deaths}}$$

##### Step-by-Step for the 5th Grader

1.  Every day, **150,000 people** die from health problems (heart attacks, cancer, old age).
2.  We delayed the solution to these problems by **8.2 years**.
3.  That means we let **449 Million people** die who would have been saved if we had arrived at the finish line on time.

#### 2. THE SUFFERING EQUATION (DALYs)

*How much life was stolen?*

In this scenario, we don't just calculate "years lost to age 80." If all disease is cured, human lifespan expands significantly (let's conservatively estimate to **100 years** healthy life).

##### The Variables

* $D_{total}$ = Total Deaths (449 Million).
* $Y_{lost}$ = Average Potential Years Lost (Conservative estimate: 25 years per person).
* $S_{factor}$ = Suffering Multiplier (For every death, there is 1 person living in misery/disability).

##### The Equation

$$H_{lost} \text{ (Healthy Years Lost)} = D_{total} \times Y_{lost}$$

##### The Calculation

$$449,000,000 \text{ people} \times 25 \text{ years}$$
$$= \mathbf{11.2 \ Billion \ Life-Years \ Lost}$$

##### Step-by-Step for the 5th Grader

1.  Those 449 million people didn't just die; they missed out on decades of life.
2.  If you add up all the birthdays they missed, it equals **11.2 Billion years**.
3.  That is more time than the Earth has existed (4.5 Billion years).

#### 3. THE ECONOMIC EQUATION (The GDP Loss)

*What is the price of delaying the future economy?*

If we cure disease, productivity explodes. No sick days, no retirement due to frailty, no medical bankruptcy. The global economy grows massive. Delaying that "Golden Age" by 8 years is incredibly expensive.

##### The Variables

* $GDP_{global}$ = Current Global GDP ($105 Trillion).
* $G_{growth}$ = Economic Growth Rate from Curing Disease (Conservative: 4%).
* $V_{year}$ = Value of a Healthy Life Year ($100,000).

##### The Equation (The "Lost Future" Valuation)

$$E_{cost} = H_{lost} \times V_{year}$$

##### The Calculation

$$11,200,000,000 \text{ Life-Years} \times \$100,000$$
$$= \mathbf{\$1.12 \ Quadrillion}$$

##### Step-by-Step for the 5th Grader

1.  A healthy person produces value (work, love, ideas). Economists say a healthy year is worth **$100,000**.
2.  We wasted **11.2 Billion** of those years.
3.  The total bill is **$1,120 Trillion Dollars**. (That is 10 times more money than exists in the entire world right now).

#### SUMMARY: THE "UPPER BOUND" DAILY RECEIPT

If we assume we *will* eventually cure all disease, but the FDA is making us wait 8 extra years for it, this is the bill we pay **every single day**.

**INVOICE: THE COST OF DELAYING THE CURE**

*Scenario: Total Eradication Delayed by 8 Years*

* **Lives Cost:** **150,000** people died today. (This is the entire population of Savannah, Georgia, wiped out every morning).
* **Time Cost:** **3.7 Million Years** of life were deleted today.
* **Money Cost:** We burned **$370 Billion** today.

##### The 5th Grader Logic

Imagine you have a winning lottery ticket worth **Infinity Dollars** (The Cure).
The government says, "You can't cash this for 8 years because we need to check if the paper is safe."
While you wait 8 years, your family starves to death.
###### That is the Upper Bound Cost.